Company news

ME Therapeutics Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

October 9, 2026

ME Therapeutics Advances In Vivo CAR and Therapeutic mRNA STING Programs

September 8, 2026

ME Therapeutics Closes Over-Subscribed Private Placement

July 17, 2026

ME Therapeutics Announces Private Placement

June 3, 2026

ME Therapeutics to Pitch at CSE Capital Tech Connect During Web Summit Vancouver

May 7, 2026

ME Therapeutics Provides Scientific Update on In Vivo CAR and Therapeutic mRNA Programs

April 29, 2026

ME Therapeutics Scientific and Corporate Update

January 30, 2026

ME Therapeutics Attending JP Morgan Healthcare Conference

January 6, 2026

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

October 16, 2025

ME Therapeutics Added to CSE25 Index

October 10, 2025

ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs

September 26, 2025

ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease

May 21, 2025

ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE

March 3, 2025

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

January 14, 2025

ME Therapeutics Holdings Inc. Appoints Chief Business Officer

October 25, 2024

ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update

October 22, 2024

ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration

September 18, 2024

ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells

July 8, 2024

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

June 13, 2024

ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial

May 29, 2024

ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities

May 17, 2024

ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024

April 15, 2024

ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

March 26, 2024

ME Therapeutics Announces Closing of Non-Brokered Private Placement

March 6, 2024

ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update

February 27, 2024

ME Therapeutics Holdings Inc. Announces Listing on the Frankfurt Stock Exchange (FSE) and the Completion of Its Redesigned Website

December 11, 2023

ME Therapeutics Holdings inc. provides an overview and update on current research and development programs

December 5, 2023

Decks